Text Size

Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study

Beckers HJM, Aptel F, Webers CAB, Bluwol E, Martínez-de-la-Casa JM, García-Feijoó J, Lachkar Y, Méndez-Hernández CD, Riss I, Shao H, Pinchuk L, Angeles R, Sadruddin O, Shaarawy TM.


  • 2021
  • Ophthalmology Glaucoma
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands; CHU de Grenoble-Alpes, Grenoble, France; University Eye Clinic, Maastricht University Medical Center, Maastricht, the Netherlands; Hôpital Paris Saint Joseph, Paris, France; Departamento de Oftalmologia Universidad Complutense, Hospital Clínico San Carlos, OFTARED, Madrid, Spain; Pôle Ophtalmologique de la Clinique Mutualiste, Bordeaux, France; Santen Inc., Emeryville, California; InnFocus Inc., a Santen Company, Miami, Florida; Hôpitaux Universitaires de Genève, Geneva, Switzerland

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group


Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.


Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022